Orexo
ISIN: SE0000736415 | Ticker: ORX | LEI: 549300LJ5CCWDPTK9Z08
Country: Sweden
Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of mental illness and substance use disorders. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for the treatment of opioid use disorder.
- Developed four commercial pharmaceutical products with worldwide approval
- Addresses unmet need within the growing space of mental illness and addiction disorders
- Broad product portfolio and development pipeline of traditional pharma products and digital therapies
- Strategic focus on portfolio expansion through development, licensing and M&A
- Strong cash generation from the business area US Pharma enabling to invest in future growth
1995
Served areaWorldwide
HeadquartersRapsgatan 7E, 75105 Uppsala – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 1,232,900,000.00 | 1,273,700,000.00 | 1,109,000,000.00 |
| Noncurrent Assets | N/A | 401,300,000.00 | 408,200,000.00 | 373,500,000.00 |
| Property Plant And Equipment | N/A | 47,300,000.00 | 65,900,000.00 | 76,100,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 252,800,000.00 | 248,900,000.00 | 217,400,000.00 |
| Deferred Tax Assets | N/A | 32,700,000.00 | 33,400,000.00 | 33,100,000.00 |
| Other Noncurrent Financial Assets | N/A | 700,000.00 | 800,000.00 | 900,000.00 |
| Current Assets | N/A | 831,600,000.00 | 865,500,000.00 | 735,500,000.00 |
| Inventories | N/A | 108,400,000.00 | 92,300,000.00 | 74,600,000.00 |
| Trade And Other Current Receivables | N/A | 165,200,000.00 | 214,000,000.00 | N/A |
| Current Trade Receivables | N/A | N/A | 214,000,000.00 | 246,500,000.00 |
| Current Prepaid Expenses | N/A | 26,900,000.00 | 31,100,000.00 | 36,600,000.00 |
| Other Current Receivables | N/A | N/A | 24,100,000.00 | 25,900,000.00 |
| Other Current Nonfinancial Assets | N/A | 25,700,000.00 | 24,100,000.00 | N/A |
| Cash and cash equivalents | 816,800,000.00 | 505,300,000.00 | 504,100,000.00 | 132,200,000.00 |
| Shortterm Deposits Not Classified As Cash Equivalents | N/A | N/A | 0.00 | 219,600,000.00 |
| Equity And Liabilities | N/A | 1,232,900,000.00 | 1,273,700,000.00 | 1,109,000,000.00 |
| Equity | 706,400,000.00 | 558,500,000.00 | 349,600,000.00 | 193,900,000.00 |
| Issued Capital | N/A | 14,200,000.00 | 14,200,000.00 | 14,200,000.00 |
| Retained Earnings | N/A | -1,256,700,000.00 | -1,480,200,000.00 | -1,657,900,000.00 |
| Share Premium | N/A | 1,814,400,000.00 | 1,816,000,000.00 | 1,815,900,000.00 |
| Other Reserves | N/A | -13,400,000.00 | -400,000.00 | N/A |
| Liabilities | N/A | 674,400,000.00 | 924,100,000.00 | N/A |
| Noncurrent Liabilities | N/A | 73,100,000.00 | 543,900,000.00 | 529,200,000.00 |
| Other Longterm Provisions | N/A | 25,700,000.00 | 13,500,000.00 | 10,200,000.00 |
| Other Noncurrent Financial Liabilities | N/A | 0.00 | 492,300,000.00 | 494,800,000.00 |
| Current Liabilities | N/A | 601,300,000.00 | 924,100,000.00 | 915,100,000.00 |
| Other Shortterm Provisions | N/A | 197,300,000.00 | 160,100,000.00 | 121,500,000.00 |
| Trade And Other Current Payables | N/A | 47,000,000.00 | 49,200,000.00 | 86,600,000.00 |
| Accruals Classified As Current | N/A | 107,200,000.00 | 133,700,000.00 | 135,600,000.00 |
| Other Current Financial Liabilities | N/A | 224,500,000.00 | 0.00 | 0.00 |
| Other Current Nonfinancial Liabilities | N/A | 6,200,000.00 | 16,900,000.00 | N/A |
| Current Accrued Expenses And Other Current Liabilities | N/A | N/A | 16,900,000.00 | 21,500,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue From Contracts With Customers | 663,600,000.00 | 565,000,000.00 | 624,300,000.00 |
| Other Income | 17,600,000.00 | 10,900,000.00 | 37,800,000.00 |
| Profit Loss From Operating Activities | -19,900,000.00 | -214,100,000.00 | -183,900,000.00 |
| Finance Income | 60,700,000.00 | 38,300,000.00 | 74,800,000.00 |
| Finance Costs | 79,100,000.00 | 46,700,000.00 | 61,400,000.00 |
| Profit Loss Before Tax | -38,300,000.00 | -222,500,000.00 | -170,400,000.00 |
| Income Tax Expense Continuing Operations | 46,100,000.00 | 1,000,000.00 | 7,200,000.00 |
| Profit (loss) | -84,400,000.00 | -223,500,000.00 | -177,600,000.00 |
| Profit Loss Attributable To Owners Of Parent | -84,400,000.00 | -223,500,000.00 | -177,600,000.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -84,400,000.00 | -223,500,000.00 | -177,600,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | 10,100,000.00 | 27,800,000.00 | 36,400,000.00 |
| Other Adjustments For Noncash Items | N/A | -7,100,000.00 | -16,800,000.00 | -3,500,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 11,800,000.00 | 22,900,000.00 | 22,400,000.00 |
| Interest Received Classified As Operating Activities | N/A | 3,000,000.00 | 0.00 | 1,400,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 600,000.00 | 8,200,000.00 | 1,500,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 16,800,000.00 | -229,000,000.00 | -156,600,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 29,400,000.00 | 24,700,000.00 | 18,800,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 160,300,000.00 | 28,100,000.00 | 5,100,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -189,100,000.00 | -52,900,000.00 | -234,700,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | N/A | 27,300,000.00 | 0.00 | N/A |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 84,000,000.00 | 239,500,000.00 | 21,400,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -111,300,000.00 | 250,600,000.00 | -21,400,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -283,700,000.00 | -31,200,000.00 | -412,800,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -27,800,000.00 | 30,000,000.00 | 40,900,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | -311,500,000.00 | -1,200,000.00 | -371,800,000.00 |
| Cash and cash equivalents | 816,800,000.00 | 505,300,000.00 | 504,100,000.00 | 132,200,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 24.02.23 | Nikolaj Arrild Sørensen | Other | Buy | SEK 188,945.00 |
| 27.01.23 | Fredrik Järrsten | Other | Buy | SEK 79,695.00 |
| 26.07.22 | Michael Matly | Other | Buy | SEK 60,777.77 |
| 21.07.22 | Charlotte Vithlani Hansson | Other | Buy | SEK 61,500.00 |
| 15.07.22 | James Noble | Other | Buy | SEK 394,252.80 |
| 15.07.22 | Staffan Lindstrand | Other | Buy | SEK 59,995.65 |
| 14.07.22 | Christine Elizabeth Rankin | Other | Buy | SEK 60,101.90 |
| 14.06.22 | Nikolaj Arrild Sørensen | Other | Buy | SEK 182,664.00 |
| 28.02.22 | Staffan Lindstrand | Other | Buy | SEK 159,984.00 |
| 25.02.22 | Nikolaj Arrild Sørensen | Other | Buy | SEK 319,500.00 |
SE0000736415
LEI549300LJ5CCWDPTK9Z08
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.